RADNOR, Pa., July 31, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced the appointment of Christopher Bouton, Ph.D., as Chief Technology Officer. In this role, Bouton will lead technology strategy and development of a next-generation integrated model-informed drug development (MIDD) platform, which is enabled by generative AI and advances in biosimulation technology.
Dr. Bouton was the founder and CEO of Vyasa Analytics, acquired by Certara in 2022. Vyasa provided scalable deep-learning software, which allows Certara software to make new predictions and answer complex questions across structured and unstructured data sources. Chris has led the development of several new Certara AI-based products, including CoAuthor ™, a generative AI product for regulatory and medical writing. Earlier in his career, Chris founded and led Entagen, an enterprise analytics software provider acquired by Thomson Reuters, and started his work in drug development as a computational biologist at Pfizer.
“Chris is a visionary leader who combines expertise in AI with experience in drug discovery and development,” said William F. Feehery, Chief Executive Officer. “His leadership has been instrumental in expanding the adoption of AI-powered biosimulation and virtual trials, helping clients achieve greater success in bringing new medicines to patients faster and with greater confidence.
Certara’s next-generation modeling platform integrates its scientific expertise, broad portfolio of solutions, and AI approaches to increase the efficiency and effectiveness of discovering and developing novel therapeutics.
“Biosimulation combined with generative AI and machine learning is redefining how new medicines are discovered and developed, and is speeding timelines, reducing costs, and improving success rates,” said Bouton. “Leading Certara’s technology strategy to build the industry’s most advanced AI and model-informed drug development platform offers a unique opportunity to advance science and deliver better outcomes for patients worldwide.”
About Certara
Certara accelerates medicines using biosimulation software, technology, and services to transform traditional drug discovery and development. Its clients include more than 2,400 biopharmaceutical companies, academic institutions, and regulatory agencies across 70 countries. Learn more at certara.com.
Certara Contact:
Sheila Rocchio
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media Contact:
Alyssa Horowitz
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$11.02 |
Daily Change: | 0.05 0.46 |
Daily Volume: | 1,148,777 |
Market Cap: | US$1.770B |
August 06, 2025 August 04, 2025 May 05, 2025 April 14, 2025 |
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MOREChimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREEnd of content
No more pages to load